EC Pharmacology And Toxicology

Oxicams (enolic acid derivatives) are a group of structurally closely related substances. They are weakly acidic and extensively bound to plasma proteins. Their mechanisms of action involve inhibition of cyclooxygenase (COX) especially type II, a key enzyme in the biosynthesis of prostaglandins in the body as well as exerting potent and irreversible inhibitory effect on platelet aggregation leading to an increased risk of bleeding in patients. Clinically, they are highly potent therapeutic agents utilized in the management of a number of human body dysfunctions namely inflammation, stiffness, acute and chronic pain syndromes associated with ankylosing spondylitis, arthrosis, osteoarthritis, rheumatoid arthritis, arthritic diseases such as acute gout, bursitis, injuries, sprains, shoulder or hip periarthritis (shoulder-hand syndrome), and tendinitis. They are also employed for short-term treatment of postoperative and post-traumatic pain.

Quantification and/or detection of oxicams in biological matrices have been accomplished by various analytical techniques namely spectrophotometric, electrochemical, immunological, titrimetric, and chromatographic methods.

 Keywords: Oxicams; Physicochemical Properties; Therapeutic Properties; Detection and Quantification in Biological Matrices

1. Loscalzo J., et al. “Human disease classification in the postgenomic era: a complex systems approach to human pathobiology”. Molecular Systems Biology 3 (2007): 124-128.
2. Gouda MA., et al. “Synthesis and Medicinal importance of oxicams and their analogues”. Synthetic Communications 19 (2017): 1709-1736.
3. Flower R., et al. “Effects of anti-inflammatory drugs on prostaglandin biosynthesis”. Nature New Biology 238 (1972): 104-106.
4. Warner TD and Mitchell JA. “Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic”. FASEB Journal 7 (2004): 790-804.
5. Olsen S., et al. “Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction”. JAMA 8 (2015): 805-814.
6. Gordon MW., et al. “Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: implications in the etiology of multiple myeloma”. Molecular Carcinogenesis10 (2015): 1060-1069.
7. Goto T., et al. “Administration of nonsteroidal anti-inflammatory drugs accelerates spontaneous healing of osteoid osteoma”. Archives of Orthopedic and Trauma Surgery5 (2011): 619-625.
8. Izadi P., et al. “Non-steroidal anti-inflammatory drugs in the environment: Where were we and how far we have come?” Environmental Pollution 267 (2020): 115370.
9. Kelley BP., et al. “Management of acute postoperative pain in hand surgery: a systematic review”. Journal of Hand Surgery8 (2015): 1610-1619.
10. Sai S., et al. “Preoperative ampiroxicam reduces postoperative pain after hand surgery”. Journal of Hand Surgery4 (2001): 377-379.
11. Walters KM and Woessner KM. “An overview of nonsteroidal antiinflammatory drug reactions”. Immunology and Allergy Clinics of North America4 (2016): 625-641.
12. Mukherjee D., et al. “Risk of cardiovascular events associated with selective COX-2 inhibitors”. JAMA8 (2001): 954-959.
13. Sehajpal S., et al. “Prodrugs of non-steroidal anti inflammatory drugs (NSAIDs): a long march towards synthesis of safer NSAIDs”. Mini Reviews in Medicinal Chemistry14 (2018): 1199-1219.
14. Olkkola KT., et al. “Pharmacokinetics of oxicam nonsteroidal anti inflammatory agents”. Clinical Pharmokinetics2 (1994): 107-120.
15. Parikh NH., et al. “Analytical methods for quantification of non-steroidal anti-inflammatory drugs in pharmaceutical and biological samples: An overview of developments in the last decade”. Arabian Journal of Chemistry1 (2024): 105446.
16. Al-Momani IF. “Indirect low-injection spectrophotometric determination of meloxicam, tenoxicam and piroxicam in pharmaceutical formulations”. Analytical Science12 (2006): 1611-1614.
17. El-Ries MA., et al. “Spectrophotometric and potentiometric determination of piroxicam and tenoxicam in pharmaceutical preparations”. Chemical and Pharmaceutical Bulletin1 (2003): 6-10.
18. Lin L., et al. “Ultrasensitive and simultaneous detection of 6 nonsteroidal anti-inflammatory drugs by colloidal gold strip sensor”. Journal of Dairy Science3 (2021): 2529-2538.
19. El Walily AFM., et al. “Simultaneous determination of tenoxicam and 2-aminopyridine using derivative spectrophotometry and high-performance liquid chromatography”. Journal of Pharmaceutical and Biomedical Analysis12 (1997): 1923-1928.
20. Martinez-Sena T., et al. “Determination of non-steroidal anti inflammatory drugs in water and urine using selective molecular imprinted polymer extraction and liquid chromatography”. Journal of Pharmaceutical and Biomedical Analysis 131 (2016): 48-53.
21. Munera-Jaramillo MI and Botero-Garces S. “Determination of tenoxicam in plasma by high-performance liquid chromatography”. Journal of Chromatography: Biomedical Science and Application2 (1993): 349-352.
22. Emara L., et al. “A simple and sensitive HPLC/UV method for determination of meloxicam in human plasma for bioavailability and bioequivalence studies”. Journal of Applied Pharmaceutical Science7 (2016): 012-019.
23. Wanwimolruk S., et al. “A simple and sensitive HPLC assay for piroxicam in plasma and its application to bioavailability study”. Journal of Liquid Chromatography12 (1991): 2373-2381.
24. Sora I., et al. “Fast RPLC-UV method on short sub-two micron particles packed column for the assay of tenoxicam in plasma samples”. Journal of Pharmaceutical and Biomedical Analysis4 (2007): 1437-1443.
25. Mason JL and Hobbs GJ. “Simple method for the analysis of tenoxicam in human plasma using high-performance liquid chromatography”. Journal of Chromatography B: Biomedical Sciences and Application2 (1995): 410-415.
26. Manousi N., et al. “Salt-induced homogeneous liquid-liquid microextraction of piroxicam and meloxicam from human urine prior to their determination by HPLC DAD”. Applied Science13 (2022): 6658.
27. Avgerinos A., et al. “Extractionless high-performance liquid chromatographic method for the simultaneous determination of piroxicam and 5’-hydroxypiroxicam in human plasma and urine”. Journal of Chromatography B: Biomedical Sciences and Application1 (1995): 142-146.
28. Milligan PA. “Determination of piroxicam and its major metabolites in the plasma, urine and bile of humans by high-performance liquid chromatography”. Journal of Chromatography B: Biomedical Science and Application 576 (1992): 121-128.
29. Sultan M., et al. “Sample pretreatment and determination of non-steroidal anti-inflammatory drugs (NSAIDs) in pharmaceutical formulations and biological samples (blood, plasma, erythrocytes) by HPLC-UV-MS and micro-HPLC”. Current Medicinal Chemistry5 (2005): 573-588.
30. Ji HY., et al. “Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry”. Journal of Chromatography B: Analytical Technology Biomedical Life Science1-2 (2005): 214-219.
31. Calvo AM., et al. “Quantification of piroxicam and 5′-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tan dem mass spectrometry following oral administration”. Journal of Pharmaceutical and Biomedical Analysis 120 (2016): 212-220.
32. Shirako J., et al. “Simultaneous determination for oxicam non-steroidal anti-inflammatory drugs in human serum by liquid chromatography-tandem mass spectrometry”. Forensic Science International1-3 (2013): 100-102.